Results 81 to 90 of about 9,302 (232)

RxNorm for drug name normalization: a case study of prescription opioids in the FDA adverse events reporting system

Frontiers in Bioinformatics
Numerous studies have been conducted on the US Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS) database to assess post-marketing reporting rates for drug safety review and risk assessment. However, the drug names in the adverse
Huyen Le, Ru Chen, Stephen Harris, Hong Fang, Beverly Lyn-Cook, Huixiao Hong, Weigong Ge, Paul Rogers, Weida Tong, Wen Zou   +9 more
doaj   +1 more source

Drug Indications Extracted from FAERS

, 2018
This dataset contains drug indications extracted from the FDA Adverse Event Reporting System (FAERS). Source code here: https://github.com/stuppie/faers Method Outline Data files are extracted from zip files, parsed from csvs, and imported into a ...
Su, Andrew I (5802689), Stupp, Gregory S, Stupp, Gregory S (5802686), Su, Andrew I   +3 more
core   +1 more source

Identification of PT signals for TXA using disproportionality analysis in FAERS.

Identification of PT signals for TXA using disproportionality analysis in FAERS.
Jing Feng (177843), Chiwei Guo (22569722), Shujuan Zhao (6317975)   +2 more
core   +1 more source

Effect of GLP‐1 receptor agonist on nutrient intake: A narrative review

Nutrition in Clinical Practice, Volume 41, Issue 5, Page 1308-1317, October 2026.
Abstract Humans have a primitive defense mechanism called metabolic adaptation that slows voluntary weight loss. It works by downregulating hormones that reduce food intake and by lowering the metabolic rate. Second‐generation GLP‐1 receptor agonists, such as semaglutide or tirzepatide, promote weight loss by targeting this hormonal system to control ...
Ken Fujioka
wiley   +1 more source

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib

, 2022
Niraparib was approved for the treatment of platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube and primary peritoneal cancer. The authors retrospectively investigated niraparib-related adverse events (AEs) through data mining of the ...
Feie Li, Yamin Shu, Juan Li, Menglin Guo, Guosong Chen   +4 more
core   +1 more source

Gastrointestinal adverse effects of GLP‐1 receptor agonists and dual GIP/GLP‐1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents

Nutrition in Clinical Practice, Volume 41, Issue 5, Page 1318-1333, October 2026.
Abstract Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1 receptor agonists have transformed the management of type 2 diabetes and obesity. Gastrointestinal (GI) adverse events are the most common limitation of these therapies and a leading cause of discontinuation ...
Vikash Singhani, Muhammad Ehsan, Sara Valencia, Ahmed Nadeem, Eisha Moazzam, Winfield Scott Butsch, Samita Garg   +6 more
wiley   +1 more source

Sinonasal Adverse Events of Immune Checkpoint Inhibitors: Pharmacovigilance Using FAERS

Background: Immune checkpoint inhibitors (ICIs) are cancer therapies with diverse toxicities, known as immune-related adverse events (irAEs). Sinonasal irAEs have been described primarily in case reports, and their population-level characteristics remain
Zhu, Kevin, Kim, Jinah, Khosla, Atulya Aman, Singh, Rohit, Orgain, Carolyn A   +4 more
core   +1 more source

Drug-Induced Gynecomastia: Data Mining and Analysis of the FDA Adverse Event Reporting System Database

Clinical Epidemiology
Xiuli Yang,1 Xiaochun Zheng,1 Miaomiao Zhang,1,2 Jinlong Huang,1,2 Ping Huang,1,* Jiangfeng Wang1,3,* 1Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital ...
Yang X, Zheng X, Zhang M, Huang J, Huang P, Wang J   +5 more
doaj  

Comparative Neurotoxicity of Polymyxin B and Colistin in Patients With Cancer

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 10, October 2026.
ABSTRACT Background The polymyxins, polymyxin B and colistin, are last‐line options for the treatment of infections caused by drug‐resistant gram‐negative organisms. The comparative neurotoxicity of these agents using contemporary dosing is poorly understood.
Samuel L. Aitken, Emily R. Aboujaoude, Jovan Borjan, Frank P. Tverdek   +3 more
wiley   +1 more source

Comparison of Infection Risks Between Various Inhaled and Intranasal Corticosteroids: A Pharmacovigilance Analysis Based on the FAERS Database

International Journal of COPD
Ying Lan,1 Die Hu,1 Shijing Huang,1 Qing Ma,1 Li Chen,2,3 Min Xu,1 Qin He1 1Department of Pharmacy, Affiliated Hospital of Southwest Jiaotong University, The Third People’s Hospital of Chengdu, Chengdu, Sichuan, 610031, People’s Republic of China ...
Lan Y, Hu D, Huang S, Ma Q, Chen L, Xu M, He Q   +6 more
doaj